PureTech Health PLC
LSE:PRTC
Intrinsic Value
PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gas... [ Read More ]
The intrinsic value of one
PRTC
stock under the Base Case scenario is
27.4
GBX.
Compared to the current market price of 212.5 GBX,
PureTech Health PLC
is
Overvalued by 87%.
PureTech Health PLC's market capitalization is 614.5m GBX.
PRTC stock price is 212.5 GBX.
PRTC stock (27.4 GBX) is 87% less than its price (212.5 GBX).
PRTC. Open DCF Valuation
PRTC stock (27.4 GBX) is 87% less than its price (212.5 GBX). Open Relative Valuation
PRTC has upside potential of 126% compared to the average analyst price target.
Open Wall St Estimates
PRTC's ROE (Return on Equity) for the past 12 months is negative and is equal to -9%.
PRTC's Revenue has dropped by 37% over the past 12 months.
PRTC has negative Operating Income for the last twelve months.
PRTC has negative Net Income for the last twelve months.
PRTC's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -35%.
PRTC's Altman Z-Score is very low and is equal to 1.73.
PRTC has negative Free Cash Flow for the last twelve months.
PRTC has negative three-year average ROE (Return on Equity): -12%. The company is not efficient at transforming stockholders' equity into net income.
PRTC's long-term assets (694m USD) exceed its long-term liabilties (180m USD).
PRTC's D/E (Debt to Equity) is very low and is equal to 0.04.
PRTC has negative three-year average ROIC (Return on Invested Capital): -25%. The company is not efficient at using invested capital to generate operating income.
PRTC's short-term assets (360m USD) exceed its short-term liabilties (49m USD).
PRTC has negative Net Debt. This means that the company has more cash and short-term investments (352m USD) than debt (20m USD).
PRTC doesn't generate enough operating income (-173m USD) to safely cover interest payments on its debt (3m USD).
Valuation Backtest
PureTech Health PLC
Run backtest to discover the historical profit from buying and selling
PRTC
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
PureTech Health PLC
Balance Sheet Decomposition
PureTech Health PLC
| Current Assets | 360.1m |
| Cash & Short-Term Investments | 352.1m |
| Receivables | 2.3m |
| Other Current Assets | 5.7m |
| Non-Current Assets | 333.5m |
| Long-Term Investments | 285.2m |
| PP&E | 21.5m |
| Intangibles | 931k |
| Other Non-Current Assets | 25.8m |
| Current Liabilities | 49.3m |
| Accounts Payable | 8.7m |
| Accrued Liabilities | 22.5m |
| Other Current Liabilities | 18m |
| Non-Current Liabilities | 130.6m |
| Long-Term Debt | 20m |
| Other Non-Current Liabilities | 110.6m |
Earnings Waterfall
PureTech Health PLC
|
Revenue
|
11.7m
USD
|
|
Operating Expenses
|
-184.5m
USD
|
|
Operating Income
|
-172.8m
USD
|
|
Other Expenses
|
125.8m
USD
|
|
Net Income
|
-47m
USD
|
Free Cash Flow Analysis
PureTech Health PLC
PRTC Profitability Score
Profitability Due Diligence
PureTech Health PLC's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
Score
PureTech Health PLC's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
PRTC Solvency Score
Solvency Due Diligence
PureTech Health PLC's solvency score is 62/100. The higher the solvency score, the more solvent the company is.
Score
PureTech Health PLC's solvency score is 62/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PRTC Price Targets Summary
PureTech Health PLC
According to Wall Street analysts, the average 1-year price target for
PRTC
is 480.76 GBX
with a low forecast of 373.7 GBX and a high forecast of 655.2 GBX.
Shareholder Return
PRTC Price
PureTech Health PLC
| Average Annual Return | 14.53% |
| Standard Deviation of Annual Returns | 41.54% |
| Max Drawdown | -67% |
| Market Capitalization | 614.5m GBX |
| Shares Outstanding | 270 209 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
PureTech Health PLC
Country
Industry
Market Cap
Dividend Yield
Description
PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. The company is headquartered in Boston, Massachusetts and currently employs 66 full-time employees. The company went IPO on 2015-06-19. The firm is engaged in discovering, developing and commercializing medicines for diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. The firm's wholly owned pipeline consists of six therapeutic candidates including LYT-100 (deupirfenidone), LYT-200, LYT-210, LYT-300 (oral allopregnanolone), LYT-500, and LYT-503/IMB-150. Its segments include Internal, Controlled Founded Entity, Non-Controlled Founded Entities, and Parent Company and Other. Its Internal segment is advancing wholly owned programs designed to harness immunological, fibrotic and lymphatic system mechanisms. These classes of immunomodulatory drugs are designed to treat serious diseases, including lung dysfunction, immuno-oncology, lymphatic, neurological and neuropsychological disorders.
Contact
IPO
Employees
Officers
The intrinsic value of one
PRTC
stock under the Base Case scenario is
27.4
GBX.
Compared to the current market price of 212.5 GBX,
PureTech Health PLC
is
Overvalued by 87%.
You don't have any saved screeners yet
